Androgen Receptor Antagonists in Castration-Resistant Prostate Cancer
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Persistent androgen receptor (AR) signaling despite low levels of serum androgens has been identified as a critical target for drug discovery in castration-resistant prostate cancer (CRPC). As proof of principle that the AR remains relevant in CRPC, 2 AR-targeted agents recently approved by the Food and Drug Administration-abiraterone and enzalutamide-have increased overall survival for patients with CRPC in the setting of prior chemotherapy. This review focuses on the AR and 2 direct antagonists, enzalutamide and ARN-509. These next-generation AR antagonists offer great promise for patients with advanced disease. Relative to conventional antiandrogens such as bicalutamide, they bind to the receptor with higher affinity, prevent nuclear translocation and DNA binding, and induce apoptosis without agonist activity in preclinical models. The success of these AR-targeted agents in the clinic has changed the landscape of therapy for patients with CRPC, and further therapeutic options building on this platform are currently in development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407 · cited 2×
“Serum androgens are reduced to the 1–2 ng/dl range.11 Notably, abiraterone acetate was the first hormonal agent targeting an oncogenic change in AR signaling proven to prolong life in men with progressive men with CRPC previously treated with docetaxel (Cougar AA-301: NCT00638690) and the first hormonal agent approved…”
BackgroundSelf-citationde Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J.-P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61389-x · Cited by 3,318 · cited 1×
“prednisone alone),(5) docetaxel (which demonstrated an overall survival benefit of 2Y3 months compared with mitoxantrone),(6,7) and more recently cabazitaxel (which has shown a survival benefit of 2Y3 months in the second-line setting for patients who have already received docetaxel).(8) Fortunately, the outlook for p…”
BackgroundEverolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863 · cited 1×
“The concept of combining hormonal therapy with PI3K/mTOR pathway inhibition has recently been validated in breast cancer in the BOLERO-2 trial.(62) This phase III study demonstrated superiority of an mTOR inhibitor (everolimus) combined with an aromatase inhibitor (exemestane) in extending progression-free survival of…”
BackgroundDevelopment of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292 · cited 4×
“These same cells were then used as a screen to select compounds that optimized growth inhibition without agonist activity, which ultimately led to the identification of enzalutamide for clinical development.(14) In the clinic, anti-tumor activity with enzalutamide was observed at the lowest dose level studied, and the…”
BackgroundMethodSelf-citationMolecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278 · cited 7×
“This trial demonstrated substantial anti-tumor activity for patients treated with MDV3100 both before and after chemotherapy, credentialing the cell-based screen used to identify the compound and other preclinical models.(13,14) There was evidence of activity based on PSA declines at all dose levels tested, with a pla…”
BackgroundMethodInfluentialA Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210702 · Cited by 1,464 · cited 3×
“FIRST-GENERATION ANTIANDROGENS The mainstay of treatment for patients with newly diagnosed advanced disease remains suppression of gonadal androgens using a gonadotropin-releasing hormone analog alone or in combination with a conventional antiandrogen such as flutamide, bicalutamide, or nilutamide, which bind to and i…”
BackgroundMontgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0249 · Cited by 1,419
Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025 · cited 1×
“These limitations of conventional antiandrogens (agonist potential and weak affinity for AR), as well as the discovery that AR gene amplification and overexpression enable prostate cancer to thrive in environments with low levels of circulating androgens, have formed the preclinical basis for developing novel second-g…”
BackgroundSelf-citationWatson, P. A., Chen, Y. F., Balbas, M. D., Wongvipat, J., Socci, N. D., Viale, A., Kim, K., & Sawyers, C. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012443107 · Cited by 639
Cited by
Organoid Cultures Derived from Patients with Advanced Prostate Cancer
Gao, D., Vela, I., Sboner, A., Iaquinta, P. J., Karthaus, W. R., Gopalan, A., Dowling, C., Wanjala, J. N., Undvall, E. A., Arora, V. K., et al. (2014) · Cell · doi:10.1016/j.cell.2014.08.016 · Cited by 1,559
Self-citationProteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery
Burslem, G. M., & Crews, C. M. (2020) · Cell · doi:10.1016/j.cell.2019.11.031 · Cited by 1,079
“Androgen receptor (AR) antagonists, such as enzalutamide (Rathkopf and Scher, 2013), have been used therapeutically with great benefit to prostate cancer patients; however, resistance often arises.”
Rathkopf, D. E., Smith, M. R., de Bono, J. S., Logothetis, C. J., Shore, N. D., de Souza, P., Fizazi, K., Mulders, P. F. A., Mainwaring, P., Hainsworth, J. D., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.02.056 · Cited by 274
Self-citationMechanisms of Taxane Resistance
Maloney, S., Spring, C., Morejon-Lasso, L., & Prosperi, J. (2020) · Cancers · doi:10.3390/cancers12113323 · Cited by 198
Benzimidazole Scaffold as Anticancer Agent: Synthetic Approaches and Structure–Activity Relationship
Shrivastava, N., Naim, M. J., Alam, M. J., Nawaz, F., Ahmed, S., & Alam, O. (2017) · Archiv der Pharmazie · doi:10.1002/ardp.201700040 · Cited by 189
Metadata
- Authors
- Rathkopf, D., & Scher, H. I.
- Venue
- The Cancer Journal
- Published
- 2013-01
- Volume
- 19
- Issue
- 1
- Pages
- 43-49
- ISSN
- 1528-9117 (ISSN-L)
- OpenAlex
- W2091098941
- Cited by
- 129
- References
- 14
- FWCI
- 11.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Androgen Receptor Antagonists in Castration-Resistant Prostate Cancer. https://app.cochat.ai/papers/10.1097/ppo.0b013e318282635a
- The paper
- Rathkopf, D., & Scher, H. I. (2013). Androgen Receptor Antagonists in Castration-Resistant Prostate Cancer. The Cancer Journal. https://doi.org/10.1097/ppo.0b013e318282635a
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.